Evidence map›Paper›PMID 25136658›Full record

ReviewTheScientificWorldJournal2014

The role of IL-33 in host response to Candida albicans.

C Rodríguez-Cerdeira, A Lopez-Bárcenas, B Sánchez-Blanco, R Arenas

Open access · goldAbstract readReview
In one paragraph

Review in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

C Rodríguez-CerdeiraDepartment of Dermatology, Hospital do Meixoeiro (CHUVI) and University of Vigo, C/Meixoeiro S/N, Vigo, 36200 Galicia, Spain.
A Lopez-BárcenasDepartment of Dermatology, Hospital General Dr. Manuel Gea González, Calzada de Tlalpan 4800, Tlalpan, 14000 México City, DF, Mexico.
B Sánchez-BlancoDepartment of Emergency, CHUVI, Hospital do Meixoeiro (CHUVI), C/Meixoeiro S/N, Vigo, 36200 Galicia, Spain.
R ArenasDepartment of Dermatology (Section of Mycology), Hospital General Dr. Manuel Gea González, Calzada de Tlalpan 4800, Tlalpan, 14000 México City, DF, Mexico.
Hospital General Dr. Manuel Gea Gonzalez · MXUniversidade de Vigo · ESUniversity Hospital Complex Of Vigo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterleukin (IL) 33 is a recently identified pleiotropic cytokine that influences the activity of multiple cell types and orchestrates complex innate and adaptive immune responses.

methodsWe performed an extensive review of the literature published between 2005 and 2013 on IL-33 and related cytokines, their functions, and their regulation of the immune system following Candida albicans colonization. Our literature review included cross-references from retrieved articles and specific data from our own studies.

resultsIL-33 (IL-1F11) is a recently identified member of the IL-1 family of cytokines. Accumulating evidence suggests a pivotal role of the IL-33/ST2 axis in host immune defense against fungal pathogens, including C. albicans. IL-33 induces a Th2-type inflammatory response and activates both innate and adaptive immunity. Studies in animal models have shown that Th2 inflammatory responses have a beneficial role in immunity against gastrointestinal and systemic infections by Candida spp.

conclusionsThis review summarizes the most important clinical studies and case reports describing the beneficial role of IL-33 in immunity and host defense mechanisms against pathogenic fungi. The finding that the IL-33/ST2 axis is involved in therapeutic target has implications for the prevention and treatment of inflammatory diseases, including acute or chronic candidiasis.

Indexed as

AnimalsCandida albicansCandidiasisHumansInterleukin-33InterleukinsIL33 protein, humanInterleukin-33Interleukins

Identifiers

PMID25136658
PMCPMC4130336
OpenAlexW2020683766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.